Enzo Biochem Inc - Asset Resilience Ratio
Enzo Biochem Inc (ENZ) has an Asset Resilience Ratio of 5.83% as of July 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore balance sheet size of Enzo Biochem Inc for the complete picture of this company's asset base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2003–2024)
This chart shows how Enzo Biochem Inc's Asset Resilience Ratio has changed over time. See how leveraged is Enzo Biochem Inc's balance sheet to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Enzo Biochem Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Enzo Biochem Inc market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $5.00 Million | 5.83% |
| Total Liquid Assets | $5.00 Million | 5.83% |
Asset Resilience Insights
- Limited Liquidity: Enzo Biochem Inc maintains only 5.83% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Enzo Biochem Inc Industry Peers by Asset Resilience Ratio
Compare Enzo Biochem Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882 |
Diagnostics & Research | 0.14% |
|
SMO ClinPlus Co. Ltd.
SHE:301257 |
Diagnostics & Research | 15.78% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
RHYTHM Biosciences Ltd
AU:RHY |
Diagnostics & Research | 2.74% |
|
Check-Cap Ltd.
NASDAQ:MBAI |
Diagnostics & Research | 2.90% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
Annual Asset Resilience Ratio for Enzo Biochem Inc (2003–2024)
The table below shows the annual Asset Resilience Ratio data for Enzo Biochem Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-07-31 | 5.83% | $5.00 Million | $85.76 Million | -61.76pp |
| 2023-07-31 | 67.59% | $82.37 Million | $121.88 Million | +45.05pp |
| 2022-07-31 | 22.54% | $21.60 Million | $95.86 Million | -15.73pp |
| 2021-07-31 | 38.26% | $43.50 Million | $113.69 Million | -4.27pp |
| 2020-07-31 | 42.53% | $47.87 Million | $112.54 Million | -13.87pp |
| 2019-07-31 | 56.40% | $60.15 Million | $106.64 Million | -2.66pp |
| 2018-07-31 | 59.06% | $60.04 Million | $101.66 Million | -0.54pp |
| 2017-07-31 | 59.60% | $64.17 Million | $107.67 Million | -1.01pp |
| 2016-07-31 | 60.61% | $67.78 Million | $111.82 Million | -- |
| 2015-07-31 | 0.00% | $0.00 | $68.39 Million | -- |
| 2014-07-31 | 0.00% | $0.00 | $64.41 Million | -- |
| 2013-07-31 | 0.00% | $0.00 | $58.96 Million | -- |
| 2012-07-31 | 0.00% | $0.00 | $69.12 Million | -- |
| 2011-07-31 | 9.13% | $10.00 Million | $109.47 Million | -12.39pp |
| 2010-07-31 | 21.53% | $24.81 Million | $115.25 Million | -11.00pp |
| 2009-07-31 | 32.53% | $43.31 Million | $133.13 Million | +26.77pp |
| 2005-07-31 | 5.76% | $6.71 Million | $116.47 Million | -9.86pp |
| 2004-07-31 | 15.63% | $17.24 Million | $110.33 Million | +2.55pp |
| 2003-07-31 | 13.08% | $15.15 Million | $115.88 Million | -- |
About Enzo Biochem Inc
Enzo Biochem, Inc., a life sciences company, engages in the labeling and detection technologies from DNA to whole cell analysis in the United States and internationally. The company offers labels, dyes, antibodies, genomic probes, immunoassays, biochemicals, and proteins are used to label, detect, and visualize a biological target of interest in drug discovery exploration and drug development pro… Read more